Analysed ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) News Sources
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
26-05-2026
yahoo.com
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus
26-05-2026
yahoo.com
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
05-06-2026
marketbeat.com
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
18-06-2026
yahoo.com
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
22-06-2026
yahoo.com
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval
24-06-2026
stocktwits.com
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
25-06-2026
247wallst.com
What is the current price of ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ)?
The current price of ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) is $76.4.
ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) since the previous trading day is $-7.6.
ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) since the previous trading day is -9.0476%.
What is the most recent average sentiment score for ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ)?
The most recent average sentiment score for ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ)?
The most recent sentiment for ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ) is .
SEC-8K** Filing Available For ARROWHEAD PHARMACEUTICALS IN (ARWR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.